Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab
INTRODUCTION[|]The present study is an evaluation of outcomes of photodynamic therapy (PDT) combined with intravitreal injections of bevacizumab for polypoidal choroidal vasculopathy (PCV) that was nonresponding to ranibizumab injections.[¤]METHODS[|]This retrospective study included 37 eyes of 37 p...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KARE Publishing
2016-12-01
|
| Series: | Beyoglu Eye Journal |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=beyoglu&un=BEJ-43153 |
| _version_ | 1797912037652692992 |
|---|---|
| author | Zeynep Alkin Abdullah Ozkaya Sibel Ahmet Okkes Baz Mesut Togac Irfan Perente Muhittin Taskapili |
| author_facet | Zeynep Alkin Abdullah Ozkaya Sibel Ahmet Okkes Baz Mesut Togac Irfan Perente Muhittin Taskapili |
| author_sort | Zeynep Alkin |
| collection | DOAJ |
| description | INTRODUCTION[|]The present study is an evaluation of outcomes of photodynamic therapy (PDT) combined with intravitreal injections of bevacizumab for polypoidal choroidal vasculopathy (PCV) that was nonresponding to ranibizumab injections.[¤]METHODS[|]This retrospective study included 37 eyes of 37 patients with PCV. Principal outcome measurements used were mean change in best corrected visual acuity (BCVA) and central macular thickness (CMT), and regression rate of polypoidal lesions.[¤]RESULTS[|]Mean follow-up time was 11.8+-7.2 months. Mean BCVA decreased significantly from 0.69+-0.42 logMAR at base- line to 0.78+-0.42 logMAR at final visit (p=0.01). BCVA improved in 9 (24.3%) eyes, decreased in 11 (29.7%), and remained stable in 17 (45.9%) eyes. Mean CMT decreased from 352.2 μm (range: 139-573 μm) at baseline to 318+-117.1 μm (range: 136–585 μm) at final visit (p=0.26). Seventeen (45.9%) eyes achieved dry macula, defined as absence of intraretinal or subretinal fluid on optical coherence tomography at 6 months. In addition, 25 eyes (67.5%) showed complete regression of polypoidal lesions.[¤]DISCUSSION AND CONCLUSION[|]PDT combined with bevacizumab may be beneficial in resolution of exudation in eyes refractory to ranibi- zumab injections. VA improvement may be obtained in limited number of eyes.[¤] |
| first_indexed | 2024-04-10T11:50:03Z |
| format | Article |
| id | doaj.art-ffa118d79f4f44cba1344c59952d53c1 |
| institution | Directory Open Access Journal |
| issn | 2587-0394 |
| language | English |
| last_indexed | 2024-04-10T11:50:03Z |
| publishDate | 2016-12-01 |
| publisher | KARE Publishing |
| record_format | Article |
| series | Beyoglu Eye Journal |
| spelling | doaj.art-ffa118d79f4f44cba1344c59952d53c12023-02-15T16:17:10ZengKARE PublishingBeyoglu Eye Journal2587-03942016-12-0111101410.14744/bej.43153BEJ-43153Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal RanibizumabZeynep Alkin0Abdullah Ozkaya1Sibel Ahmet2Okkes Baz3Mesut Togac4Irfan Perente5Muhittin Taskapili6Beyoglu Eye Training and Research Hospital, Istanbul, TurkeyBeyoglu Eye Training and Research Hospital, Istanbul, TurkeyBeyoglu Eye Training and Research Hospital, Istanbul, TurkeyBeyoglu Eye Training and Research Hospital, Istanbul, TurkeyBeyoglu Eye Training and Research Hospital, Istanbul, TurkeyBeyoglu Eye Training and Research Hospital, Istanbul, TurkeyBeyoglu Eye Training and Research Hospital, Istanbul, TurkeyINTRODUCTION[|]The present study is an evaluation of outcomes of photodynamic therapy (PDT) combined with intravitreal injections of bevacizumab for polypoidal choroidal vasculopathy (PCV) that was nonresponding to ranibizumab injections.[¤]METHODS[|]This retrospective study included 37 eyes of 37 patients with PCV. Principal outcome measurements used were mean change in best corrected visual acuity (BCVA) and central macular thickness (CMT), and regression rate of polypoidal lesions.[¤]RESULTS[|]Mean follow-up time was 11.8+-7.2 months. Mean BCVA decreased significantly from 0.69+-0.42 logMAR at base- line to 0.78+-0.42 logMAR at final visit (p=0.01). BCVA improved in 9 (24.3%) eyes, decreased in 11 (29.7%), and remained stable in 17 (45.9%) eyes. Mean CMT decreased from 352.2 μm (range: 139-573 μm) at baseline to 318+-117.1 μm (range: 136–585 μm) at final visit (p=0.26). Seventeen (45.9%) eyes achieved dry macula, defined as absence of intraretinal or subretinal fluid on optical coherence tomography at 6 months. In addition, 25 eyes (67.5%) showed complete regression of polypoidal lesions.[¤]DISCUSSION AND CONCLUSION[|]PDT combined with bevacizumab may be beneficial in resolution of exudation in eyes refractory to ranibi- zumab injections. VA improvement may be obtained in limited number of eyes.[¤]https://jag.journalagent.com/z4/download_fulltext.asp?pdir=beyoglu&un=BEJ-43153bevacizumabphotodynamic therapypolypoidal choroidal vasculopathyranibizumab. |
| spellingShingle | Zeynep Alkin Abdullah Ozkaya Sibel Ahmet Okkes Baz Mesut Togac Irfan Perente Muhittin Taskapili Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab Beyoglu Eye Journal bevacizumab photodynamic therapy polypoidal choroidal vasculopathy ranibizumab. |
| title | Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab |
| title_full | Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab |
| title_fullStr | Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab |
| title_full_unstemmed | Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab |
| title_short | Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab |
| title_sort | photodynamic therapy and bevacizumab combination for polypoidal choroidal vasculopathy refractory to intravitreal ranibizumab |
| topic | bevacizumab photodynamic therapy polypoidal choroidal vasculopathy ranibizumab. |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=beyoglu&un=BEJ-43153 |
| work_keys_str_mv | AT zeynepalkin photodynamictherapyandbevacizumabcombinationforpolypoidalchoroidalvasculopathyrefractorytointravitrealranibizumab AT abdullahozkaya photodynamictherapyandbevacizumabcombinationforpolypoidalchoroidalvasculopathyrefractorytointravitrealranibizumab AT sibelahmet photodynamictherapyandbevacizumabcombinationforpolypoidalchoroidalvasculopathyrefractorytointravitrealranibizumab AT okkesbaz photodynamictherapyandbevacizumabcombinationforpolypoidalchoroidalvasculopathyrefractorytointravitrealranibizumab AT mesuttogac photodynamictherapyandbevacizumabcombinationforpolypoidalchoroidalvasculopathyrefractorytointravitrealranibizumab AT irfanperente photodynamictherapyandbevacizumabcombinationforpolypoidalchoroidalvasculopathyrefractorytointravitrealranibizumab AT muhittintaskapili photodynamictherapyandbevacizumabcombinationforpolypoidalchoroidalvasculopathyrefractorytointravitrealranibizumab |